| Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars (NCT05585112) | Latakia University | 2022-10-17 |
| Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study (NCT05393713) | Mayo Clinic | 2022-10-17 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions (NCT05548543) | Hanmi Pharmaceutical Company Limited | 2022-10-17 |
| A Study to Learn About Study Medicine Called PF-07261271 in Healthy People (NCT05536440) | Pfizer | 2022-10-17 |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects (NCT05476497) | Allergy Therapeutics | 2022-10-17 |
| SB17170 Phase 1 Clinical Trial in Solid Tumors (NCT05522868) | SPARK Biopharma | 2022-10-17 |
| IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients (NCT05641545) | SLK Kliniken Heilbronn GmbH | 2022-10-17 |
| A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants (NCT05573230) | Eli Lilly and Company | 2022-10-17 |
| 4D-310 in Adults With Fabry Disease and Cardiac Involvement (NCT05629559) | 4D Molecular Therapeutics | 2022-10-16 |
| A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects (NCT05542303) | Zenas BioPharma (USA), LLC | 2022-10-16 |
| Study on Human Mass Balance of SPH3127 Tablets (NCT05593562) | Shanghai Pharmaceuticals Holding Co., Ltd | 2022-10-16 |
| Glutamatergic Mechanisms: Aim2 (NCT05401227) | New York State Psychiatric Institute | 2022-10-15 |
| Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers (NCT05597241) | Syndeio Biosciences, Inc | 2022-10-15 |
| Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (NCT05261321) | University of British Columbia | 2022-10-15 |
| A Study of ASKG315 in Patients With Advanced Solid Tumors. (NCT05554666) | AskGene Pharma, Inc. | 2022-10-15 |
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (NCT05576181) | Fundamenta Therapeutics, Ltd. | 2022-10-15 |
| Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults. (NCT05625334) | Vectura, Inc. | 2022-10-14 |
| Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment (NCT05560464) | Vertex Pharmaceuticals Incorporated | 2022-10-14 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old (NCT05585632) | ModernaTX, Inc. | 2022-10-14 |
| A Study of STSA-1002 in Healthy Subjects (NCT05497635) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2022-10-14 |
| A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) (NCT05360160) | M.D. Anderson Cancer Center | 2022-10-14 |
| Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART (NCT05604209) | University of North Carolina, Chapel Hill | 2022-10-13 |
| Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (NCT05201352) | Centre Georges Francois Leclerc | 2022-10-13 |
| Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM (NCT05438394) | Peking University People's Hospital | 2022-10-13 |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases (NCT05341349) | Emory University | 2022-10-13 |
| Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics (NCT05578846) | Alexion Pharmaceuticals, Inc. | 2022-10-13 |
| A Phase 1, First-in-human Study of VX-634 (NCT05579431) | Vertex Pharmaceuticals Incorporated | 2022-10-13 |
| A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants (NCT05460455) | Shanghai Huaota Biopharmaceutical Co., Ltd. | 2022-10-13 |
| First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts (NCT05576012) | Lipum AB | 2022-10-13 |
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations (NCT05271916) | Shanghai Chest Hospital | 2022-10-13 |
| Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air (NCT05680831) | Martin W. Case | 2022-10-13 |
| Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function (NCT05488678) | Basilea Pharmaceutica | 2022-10-12 |
| SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects (NCT05528315) | Autobahn Therapeutics, Inc. | 2022-10-12 |
| Study of Oral MRT-2359 in Selected Cancer Patients (NCT05546268) | Monte Rosa Therapeutics, Inc | 2022-10-12 |
| A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects (NCT06681493) | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2022-10-12 |
| Diet Effect on Cancer Treatment Outcome (NCT05410002) | Optimal Health Research | 2022-10-12 |
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (NCT05379946) | InventisBio Co., Ltd | 2022-10-12 |
| A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease (NCT05541627) | AskBio France, SAS, a subsidiary of AskBio Inc. | 2022-10-12 |
| a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (NCT06166836) | InxMed (Shanghai) Co., Ltd. | 2022-10-12 |
| A Trial of HR17031 Injection With Renal Insufficiency (NCT05292495) | Jiangsu HengRui Medicine Co., Ltd. | 2022-10-12 |
| D-Cycloserine+iTBS PK Study (NCT05731323) | University of Calgary | 2022-10-12 |
| A Phase I Study of GC101 TIL in Advanced Solid Tumors (NCT05417750) | Shanghai Juncell Therapeutics | 2022-10-12 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus (NCT05516966) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2022-10-12 |
| A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants (NCT05563454) | Bayer | 2022-10-11 |
| Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults (NCT05516316) | EpiEndo Pharmaceuticals | 2022-10-11 |
| A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (NCT05569421) | AstraZeneca | 2022-10-11 |
| A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer (NCT05662670) | Suzhou Junjing BioSciences Co., Ltd. | 2022-10-11 |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (NCT05537740) | Bayer | 2022-10-11 |
| A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval (NCT05309902) | Takeda | 2022-10-11 |
| A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood (NCT05550636) | Boehringer Ingelheim | 2022-10-11 |
| MAD Study of IA-14069 (NCT05533372) | ILAb Co., Ltd. | 2022-10-10 |
| A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI (NCT05348772) | Amniotics AB | 2022-10-10 |
| A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer (NCT05586516) | iOnctura | 2022-10-10 |
| Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (NCT05595460) | RayzeBio, Inc. | 2022-10-10 |
| Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) (NCT05468502) | Shanghai Life Science & Technology | 2022-10-10 |
| Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers (NCT05750355) | Vigonvita Life Sciences | 2022-10-10 |
| Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands) (NCT05804721) | Genuine Research Center, Egypt | 2022-10-10 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (NCT06005792) | Xencor, Inc. | 2022-10-10 |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 (NCT05557045) | Jazz Pharmaceuticals | 2022-10-10 |
| A Phase I Intravesical PPM Therapy for NMIBC (NCT05519241) | VA Office of Research and Development | 2022-10-10 |
| A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec (NCT05575011) | Biogen | 2022-10-10 |
| Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects (NCT05604287) | IlDong Pharmaceutical Co Ltd | 2022-10-10 |
| Relative Bioavailability and Food Effect Study of CVN424 (NCT05635461) | Cerevance Beta, Inc. | 2022-10-09 |
| Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer (NCT07632365) | Shanghai Chest Hospital | 2022-10-09 |
| Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease (NCT05601830) | Institute of Hematology & Blood Diseases Hospital, China | 2022-10-09 |
| A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer (NCT05509790) | Eli Lilly and Company | 2022-10-09 |
| Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency (NCT05505955) | Chengdu Suncadia Medicine Co., Ltd. | 2022-10-08 |
| Effects of Intravenous Lidocaine on ED50, ED95 and NTI Values of Propofol Induced Unconsciousness (NCT05573191) | General Hospital of Ningxia Medical University | 2022-10-08 |
| A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People. (NCT05554237) | Pfizer | 2022-10-07 |
| Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation (NCT05570539) | Bellus Health Inc. - a GSK company | 2022-10-07 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (NCT05514990) | University of Southern California | 2022-10-07 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (NCT05523141) | Ascletis Pharmaceuticals Co., Ltd. | 2022-10-07 |
| A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects (NCT05561530) | Aligos Therapeutics | 2022-10-07 |
| Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI (NCT04347135) | Annie (Annie) T. Packard | 2022-10-07 |
| First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging (NCT05335811) | M.D. Anderson Cancer Center | 2022-10-06 |
| Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS. (NCT05489406) | Radboud University Medical Center | 2022-10-06 |
| Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases (NCT05481658) | Nicholas Gulati | 2022-10-06 |
| A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease (NCT05521191) | Regulus Therapeutics Inc. | 2022-10-06 |
| Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML (NCT05569512) | Malika Kapadia | 2022-10-06 |
| High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD) (NCT05587673) | Stanford University | 2022-10-06 |
| Home-based EEG Neurofeedback for Chronic Neuropathic Pain (NCT05464199) | East Kent Hospitals University NHS Foundation Trust | 2022-10-06 |
| Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects (NCT05594615) | Enanta Pharmaceuticals, Inc | 2022-10-06 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (NCT05572684) | NextCure, Inc. | 2022-10-06 |
| Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. (NCT05594602) | Enanta Pharmaceuticals, Inc | 2022-10-06 |
| A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 (NCT05406583) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-10-05 |
| A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104) (NCT05571345) | Ensysce Biosciences | 2022-10-05 |
| Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (NCT05275868) | Novartis Pharmaceuticals | 2022-10-05 |
| SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (NCT05412082) | University of Miami | 2022-10-05 |
| Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (NCT05372614) | National Cancer Institute (NCI) | 2022-10-05 |
| A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma (NCT05574114) | Memorial Sloan Kettering Cancer Center | 2022-10-05 |
| A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants (NCT05579860) | Ionis Pharmaceuticals, Inc. | 2022-10-05 |
| A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (NCT05187832) | Kind Pharmaceuticals LLC | 2022-10-05 |
| Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (NCT05548439) | VBI Vaccines Inc. | 2022-10-05 |
| A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants (NCT05603312) | MeiraGTx, LLC | 2022-10-05 |
| A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (NCT05514496) | Nalo Therapeutics Inc. | 2022-10-05 |
| A Phase I Study of LY3471851 in Healthy Participants (NCT05565729) | Nektar Therapeutics | 2022-10-05 |
| Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab (NCT05206357) | Genmab | 2022-10-04 |
| A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment (NCT05517525) | Insmed Incorporated | 2022-10-04 |
| A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years (NCT05561673) | GlaxoSmithKline | 2022-10-04 |
| A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment (NCT05556798) | Memorial Sloan Kettering Cancer Center | 2022-10-04 |